USA Antisense & RNAi Therapeutics Market Professional Research Report 2022-2027, Segmented by Players, Types, End-Users in Major Regions

  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • This report offers an overview of the market trends, drivers, and barriers with respect to the USA Antisense & RNAi Therapeutics market. It also provides a detailed overview of the market of different regions across West USA, South USA, Middle West USA, Northeast USA. The report deeply analyzes type and application in the USA Antisense & RNAi Therapeutics market. Detailed analysis of key players, along with key growth strategies adopted by Antisense & RNAi Therapeutics industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.

    By Player:

    • Antisense Therapeutics Ltd

    • Enzon Pharmaceuticals Inc

    • Lorus Therapeutics (Aptose Biosciences)

    • Marina Biosciences

    • iCo Therapeutics

    • Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc)

    • Bio-Path Holdings Inc

    • OncoGeneX Pharmaceuticals

    • GlaxoSmithKline Plc

    • Mirna Therapeutics Inc

    • Ionis Pharmaceuticals

    • Olix Pharmaceuticals

    • Rexahn Pharmaceuticals

    • Acuitas Therapeutics

    • Silence Therapeutics Plc

    • miRagen Therapeutics

    • Benitec Biopharma

    • Gene Signal

    • Alnylam Pharmaceuticals

    • Quark Pharmaceuticals

    • Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)

    • Sanofi-Genzyme

    • Gradalis

    By Type:

    • RNA Interference

    • SiRNA

    • MiRNA

    • Antisense RNA

    By End-User:

    • Oncology

    • Cardiovascular

    • Renal

    • Neurodegenerative

    • Respiratory

    • Genetic

    • Infectious Diseases

    By Region:

    • West USA

    • South USA

    • Middle West USA

    • Northeast USA

  • TABLE OF CONTENT

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Antisense & RNAi Therapeutics Market

    • 1.3 Market Segment by Type

      • 1.3.1 USA Antisense & RNAi Therapeutics Market Size and Growth Rate of RNA Interference from 2016 to 2027

      • 1.3.2 USA Antisense & RNAi Therapeutics Market Size and Growth Rate of SiRNA from 2016 to 2027

      • 1.3.3 USA Antisense & RNAi Therapeutics Market Size and Growth Rate of MiRNA from 2016 to 2027

      • 1.3.4 USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Antisense RNA from 2016 to 2027

    • 1.4 Market Segment by Application

      • 1.4.1 USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Oncology from 2016 to 2027

      • 1.4.2 USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Cardiovascular from 2016 to 2027

      • 1.4.3 USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Renal from 2016 to 2027

      • 1.4.4 USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Neurodegenerative from 2016 to 2027

      • 1.4.5 USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Respiratory from 2016 to 2027

      • 1.4.6 USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Genetic from 2016 to 2027

      • 1.4.7 USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Infectious Diseases from 2016 to 2027

    • 1.5 Market Segment by Regions

      • 1.5.1 West USA Antisense & RNAi Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.2 South USA Antisense & RNAi Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.3 Middle West USA Antisense & RNAi Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027

      • 1.5.4 Northeast USA Antisense & RNAi Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    • 2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry

    3 Segmentation of Antisense & RNAi Therapeutics Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Products Types of Major Vendors

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Antisense & RNAi Therapeutics by Major Types

      • 3.4.1 Market Size and Growth Rate of RNA Interference

      • 3.4.2 Market Size and Growth Rate of SiRNA

      • 3.4.3 Market Size and Growth Rate of MiRNA

      • 3.4.4 Market Size and Growth Rate of Antisense RNA

    4 Segmentation of Antisense & RNAi Therapeutics Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Antisense & RNAi Therapeutics by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Antisense & RNAi Therapeutics in Oncology

      • 4.4.2 Market Size and Growth Rate of Antisense & RNAi Therapeutics in Cardiovascular

      • 4.4.3 Market Size and Growth Rate of Antisense & RNAi Therapeutics in Renal

      • 4.4.4 Market Size and Growth Rate of Antisense & RNAi Therapeutics in Neurodegenerative

      • 4.4.5 Market Size and Growth Rate of Antisense & RNAi Therapeutics in Respiratory

      • 4.4.6 Market Size and Growth Rate of Antisense & RNAi Therapeutics in Genetic

      • 4.4.7 Market Size and Growth Rate of Antisense & RNAi Therapeutics in Infectious Diseases

    5 Market Analysis by Regions

    • 5.1 USA Antisense & RNAi Therapeutics Production Analysis by Regions

    • 5.2 USA Antisense & RNAi Therapeutics Consumption Analysis by Regions

    • 5.3 Coronavirus (COVID-19) Impact on USA Economy

    6 West USA Antisense & RNAi Therapeutics Landscape Analysis

    • 6.1 West USA Antisense & RNAi Therapeutics Landscape Analysis by Major Types

    • 6.2 West USA Antisense & RNAi Therapeutics Landscape Analysis by Major End-Users

    7 South USA Antisense & RNAi Therapeutics Landscape Analysis

    • 7.1 South USA Antisense & RNAi Therapeutics Landscape Analysis by Major Types

    • 7.2 South USA Antisense & RNAi Therapeutics Landscape Analysis by Major End-Users

    8 Middle West USA Antisense & RNAi Therapeutics Landscape Analysis

    • 8.1 Middle West USA Antisense & RNAi Therapeutics Landscape Analysis by Major Types

    • 8.2 Middle West USA Antisense & RNAi Therapeutics Landscape Analysis by Major End-Users

    9 Northeast USA Antisense & RNAi Therapeutics Landscape Analysis

    • 9.1 Northeast USA Antisense & RNAi Therapeutics Landscape Analysis by Major Types

    • 9.2 Northeast USA Antisense & RNAi Therapeutics Landscape Analysis by Major End-Users

    10 Major Players Profiles

      • 10.1 Antisense Therapeutics Ltd

        • 10.1.1 Antisense Therapeutics Ltd Company Profile and Recent Development

        • 10.1.2 Market Performance

        • 10.1.3 Product and Service Introduction

      • 10.2 Enzon Pharmaceuticals Inc

        • 10.2.1 Enzon Pharmaceuticals Inc Company Profile and Recent Development

        • 10.2.2 Market Performance

        • 10.2.3 Product and Service Introduction

      • 10.3 Lorus Therapeutics (Aptose Biosciences)

        • 10.3.1 Lorus Therapeutics (Aptose Biosciences) Company Profile and Recent Development

        • 10.3.2 Market Performance

        • 10.3.3 Product and Service Introduction

      • 10.4 Marina Biosciences

        • 10.4.1 Marina Biosciences Company Profile and Recent Development

        • 10.4.2 Market Performance

        • 10.4.3 Product and Service Introduction

      • 10.5 iCo Therapeutics

        • 10.5.1 iCo Therapeutics Company Profile and Recent Development

        • 10.5.2 Market Performance

        • 10.5.3 Product and Service Introduction

      • 10.6 Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc)

        • 10.6.1 Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc) Company Profile and Recent Development

        • 10.6.2 Market Performance

        • 10.6.3 Product and Service Introduction

      • 10.7 Bio-Path Holdings Inc

        • 10.7.1 Bio-Path Holdings Inc Company Profile and Recent Development

        • 10.7.2 Market Performance

        • 10.7.3 Product and Service Introduction

      • 10.8 OncoGeneX Pharmaceuticals

        • 10.8.1 OncoGeneX Pharmaceuticals Company Profile and Recent Development

        • 10.8.2 Market Performance

        • 10.8.3 Product and Service Introduction

      • 10.9 GlaxoSmithKline Plc

        • 10.9.1 GlaxoSmithKline Plc Company Profile and Recent Development

        • 10.9.2 Market Performance

        • 10.9.3 Product and Service Introduction

      • 10.10 Mirna Therapeutics Inc

        • 10.10.1 Mirna Therapeutics Inc Company Profile and Recent Development

        • 10.10.2 Market Performance

        • 10.10.3 Product and Service Introduction

      • 10.11 Ionis Pharmaceuticals

        • 10.11.1 Ionis Pharmaceuticals Company Profile and Recent Development

        • 10.11.2 Market Performance

        • 10.11.3 Product and Service Introduction

      • 10.12 Olix Pharmaceuticals

        • 10.12.1 Olix Pharmaceuticals Company Profile and Recent Development

        • 10.12.2 Market Performance

        • 10.12.3 Product and Service Introduction

      • 10.13 Rexahn Pharmaceuticals

        • 10.13.1 Rexahn Pharmaceuticals Company Profile and Recent Development

        • 10.13.2 Market Performance

        • 10.13.3 Product and Service Introduction

      • 10.14 Acuitas Therapeutics

        • 10.14.1 Acuitas Therapeutics Company Profile and Recent Development

        • 10.14.2 Market Performance

        • 10.14.3 Product and Service Introduction

      • 10.15 Silence Therapeutics Plc

        • 10.15.1 Silence Therapeutics Plc Company Profile and Recent Development

        • 10.15.2 Market Performance

        • 10.15.3 Product and Service Introduction

      • 10.16 miRagen Therapeutics

        • 10.16.1 miRagen Therapeutics Company Profile and Recent Development

        • 10.16.2 Market Performance

        • 10.16.3 Product and Service Introduction

      • 10.17 Benitec Biopharma

        • 10.17.1 Benitec Biopharma Company Profile and Recent Development

        • 10.17.2 Market Performance

        • 10.17.3 Product and Service Introduction

      • 10.18 Gene Signal

        • 10.18.1 Gene Signal Company Profile and Recent Development

        • 10.18.2 Market Performance

        • 10.18.3 Product and Service Introduction

      • 10.19 Alnylam Pharmaceuticals

        • 10.19.1 Alnylam Pharmaceuticals Company Profile and Recent Development

        • 10.19.2 Market Performance

        • 10.19.3 Product and Service Introduction

      • 10.20 Quark Pharmaceuticals

        • 10.20.1 Quark Pharmaceuticals Company Profile and Recent Development

        • 10.20.2 Market Performance

        • 10.20.3 Product and Service Introduction

      • 10.21 Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)

        • 10.21.1 Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals) Company Profile and Recent Development

        • 10.21.2 Market Performance

        • 10.21.3 Product and Service Introduction

      • 10.22 Sanofi-Genzyme

        • 10.22.1 Sanofi-Genzyme Company Profile and Recent Development

        • 10.22.2 Market Performance

        • 10.22.3 Product and Service Introduction

      • 10.23 Gradalis

        • 10.23.1 Gradalis Company Profile and Recent Development

        • 10.23.2 Market Performance

        • 10.23.3 Product and Service Introduction

    The List of Tables and Figures

    • Figure Product Picture

    • Figure USA Antisense & RNAi Therapeutics Market Size and Growth Rate of RNA Interference from 2016 to 2027

    • Figure USA Antisense & RNAi Therapeutics Market Size and Growth Rate of SiRNA from 2016 to 2027

    • Figure USA Antisense & RNAi Therapeutics Market Size and Growth Rate of MiRNA from 2016 to 2027

    • Figure USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Antisense RNA from 2016 to 2027

    • Figure Market Share by Type in 2016

    • Figure Market Share by Type in 2020

    • Figure Market Share by Type in 2027

    • Figure USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Oncology from 2016 to 2027

    • Figure USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Cardiovascular from 2016 to 2027

    • Figure USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Renal from 2016 to 2027

    • Figure USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Neurodegenerative from 2016 to 2027

    • Figure USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Respiratory from 2016 to 2027

    • Figure USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Genetic from 2016 to 2027

    • Figure USA Antisense & RNAi Therapeutics Market Size and Growth Rate of Infectious Diseases from 2016 to 2027

    • Figure Market Share by End-User in 2016

    • Figure Market Share by End-User in 2020

    • Figure Market Share by End-User in 2027

    • Figure West USA Antisense & RNAi Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure South USA Antisense & RNAi Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Middle West USA Antisense & RNAi Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Northeast USA Antisense & RNAi Therapeutics Consumption Market Size and Growth Rate from 2016 to 2027

    • Figure Development Trends and Industry Dynamics of Antisense & RNAi Therapeutics Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 3 Players in 2019

    • Figure Market Share of TOP 5 Players in 2019

    • Figure Market Share of TOP 6 Players from 2016 to 2020

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Figure Coronavirus (COVID-19) Distribution Map of USA

    • Table Coronavirus (COVID-19) Impact on the Industry

    • Figure Specifications of Different Types of Antisense & RNAi Therapeutics

    • Figure Development Trends of Different Types

    • Table Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Antisense & RNAi Therapeutics by Different Types from 2016 to 2027

    • Table Consumption Share of Antisense & RNAi Therapeutics by Different Types from 2016 to 2027

    • Figure Market Size and Growth Rate of RNA Interference

    • Figure Market Size and Growth Rate of SiRNA

    • Figure Market Size and Growth Rate of MiRNA

    • Figure Market Size and Growth Rate of Antisense RNA

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Figure Consumption of Antisense & RNAi Therapeutics by Different End-Users from 2016 to 2027

    • Table Consumption Share of Antisense & RNAi Therapeutics by Different End-Users from 2016 to 2027

    • Figure Market Size and Growth Rate of Oncology

    • Figure Market Size and Growth Rate of Cardiovascular

    • Figure Market Size and Growth Rate of Renal

    • Figure Market Size and Growth Rate of Neurodegenerative

    • Figure Market Size and Growth Rate of Respiratory

    • Figure Market Size and Growth Rate of Genetic

    • Figure Market Size and Growth Rate of Infectious Diseases

    • Table USA Antisense & RNAi Therapeutics Production by Regions

    • Table USA Antisense & RNAi Therapeutics Production Share by Regions

    • Figure USA Antisense & RNAi Therapeutics Production Share by Regions in 2016

    • Figure USA Antisense & RNAi Therapeutics Production Share by Regions in 2021

    • Figure USA Antisense & RNAi Therapeutics Production Share by Regions in 2027

    • Table USA Antisense & RNAi Therapeutics Consumption by Regions

    • Table USA Antisense & RNAi Therapeutics Consumption Share by Regions

    • Figure USA Antisense & RNAi Therapeutics Consumption Share by Regions in 2016

    • Figure USA Antisense & RNAi Therapeutics Consumption Share by Regions in 2021

    • Figure USA Antisense & RNAi Therapeutics Consumption Share by Regions in 2027

    • Table West USA Antisense & RNAi Therapeutics Consumption by Types from 2016 to 2027

    • Table West USA Antisense & RNAi Therapeutics Consumption Share by Types from 2016 to 2027

    • Figure West USA Antisense & RNAi Therapeutics Consumption Share by Types in 2016

    • Figure West USA Antisense & RNAi Therapeutics Consumption Share by Types in 2021

    • Figure West USA Antisense & RNAi Therapeutics Consumption Share by Types in 2027

    • Table West USA Antisense & RNAi Therapeutics Consumption by End-Users from 2016 to 2027

    • Table West USA Antisense & RNAi Therapeutics Consumption Share by End-Users from 2016 to 2027

    • Figure West USA Antisense & RNAi Therapeutics Consumption Share by End-Users in 2016

    • Figure West USA Antisense & RNAi Therapeutics Consumption Share by End-Users in 2021

    • Figure West USA Antisense & RNAi Therapeutics Consumption Share by End-Users in 2027

    • Table South USA Antisense & RNAi Therapeutics Consumption by Types from 2016 to 2027

    • Table South USA Antisense & RNAi Therapeutics Consumption Share by Types from 2016 to 2027

    • Figure South USA Antisense & RNAi Therapeutics Consumption Share by Types in 2016

    • Figure South USA Antisense & RNAi Therapeutics Consumption Share by Types in 2021

    • Figure South USA Antisense & RNAi Therapeutics Consumption Share by Types in 2027

    • Table South USA Antisense & RNAi Therapeutics Consumption by End-Users from 2016 to 2027

    • Table South USA Antisense & RNAi Therapeutics Consumption Share by End-Users from 2016 to 2027

    • Figure South USA Antisense & RNAi Therapeutics Consumption Share by End-Users in 2016

    • Figure South USA Antisense & RNAi Therapeutics Consumption Share by End-Users in 2021

    • Figure South USA Antisense & RNAi Therapeutics Consumption Share by End-Users in 2027

    • Table Middle West USA Antisense & RNAi Therapeutics Consumption by Types from 2016 to 2027

    • Table Middle West USA Antisense & RNAi Therapeutics Consumption Share by Types from 2016 to 2027

    • Figure Middle West USA Antisense & RNAi Therapeutics Consumption Share by Types in 2016

    • Figure Middle West USA Antisense & RNAi Therapeutics Consumption Share by Types in 2021

    • Figure Middle West USA Antisense & RNAi Therapeutics Consumption Share by Types in 2027

    • Table Middle West USA Antisense & RNAi Therapeutics Consumption by End-Users from 2016 to 2027

    • Table Middle West USA Antisense & RNAi Therapeutics Consumption Share by End-Users from 2016 to 2027

    • Figure Middle West USA Antisense & RNAi Therapeutics Consumption Share by End-Users in 2016

    • Figure Middle West USA Antisense & RNAi Therapeutics Consumption Share by End-Users in 2021

    • Figure Middle West USA Antisense & RNAi Therapeutics Consumption Share by End-Users in 2027

    • Table Northeast USA Antisense & RNAi Therapeutics Consumption by Types from 2016 to 2027

    • Table Northeast USA Antisense & RNAi Therapeutics Consumption Share by Types from 2016 to 2027

    • Figure Northeast USA Antisense & RNAi Therapeutics Consumption Share by Types in 2016

    • Figure Northeast USA Antisense & RNAi Therapeutics Consumption Share by Types in 2021

    • Figure Northeast USA Antisense & RNAi Therapeutics Consumption Share by Types in 2027

    • Table Northeast USA Antisense & RNAi Therapeutics Consumption by End-Users from 2016 to 2027

    • Table Northeast USA Antisense & RNAi Therapeutics Consumption Share by End-Users from 2016 to 2027

    • Figure Northeast USA Antisense & RNAi Therapeutics Consumption Share by End-Users in 2016

    • Figure Northeast USA Antisense & RNAi Therapeutics Consumption Share by End-Users in 2021

    • Figure Northeast USA Antisense & RNAi Therapeutics Consumption Share by End-Users in 2027

    • Table Company Profile and Development Status of Antisense Therapeutics Ltd

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Antisense Therapeutics Ltd

    • Figure Sales and Growth Rate Analysis of Antisense Therapeutics Ltd

    • Figure Revenue and Market Share Analysis of Antisense Therapeutics Ltd

    • Table Product and Service Introduction of Antisense Therapeutics Ltd

    • Table Company Profile and Development Status of Enzon Pharmaceuticals Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Enzon Pharmaceuticals Inc

    • Figure Sales and Growth Rate Analysis of Enzon Pharmaceuticals Inc

    • Figure Revenue and Market Share Analysis of Enzon Pharmaceuticals Inc

    • Table Product and Service Introduction of Enzon Pharmaceuticals Inc

    • Table Company Profile and Development Status of Lorus Therapeutics (Aptose Biosciences)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Lorus Therapeutics (Aptose Biosciences)

    • Figure Sales and Growth Rate Analysis of Lorus Therapeutics (Aptose Biosciences)

    • Figure Revenue and Market Share Analysis of Lorus Therapeutics (Aptose Biosciences)

    • Table Product and Service Introduction of Lorus Therapeutics (Aptose Biosciences)

    • Table Company Profile and Development Status of Marina Biosciences

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Marina Biosciences

    • Figure Sales and Growth Rate Analysis of Marina Biosciences

    • Figure Revenue and Market Share Analysis of Marina Biosciences

    • Table Product and Service Introduction of Marina Biosciences

    • Table Company Profile and Development Status of iCo Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of iCo Therapeutics

    • Figure Sales and Growth Rate Analysis of iCo Therapeutics

    • Figure Revenue and Market Share Analysis of iCo Therapeutics

    • Table Product and Service Introduction of iCo Therapeutics

    • Table Company Profile and Development Status of Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc)

    • Figure Sales and Growth Rate Analysis of Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc)

    • Figure Revenue and Market Share Analysis of Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc)

    • Table Product and Service Introduction of Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc)

    • Table Company Profile and Development Status of Bio-Path Holdings Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bio-Path Holdings Inc

    • Figure Sales and Growth Rate Analysis of Bio-Path Holdings Inc

    • Figure Revenue and Market Share Analysis of Bio-Path Holdings Inc

    • Table Product and Service Introduction of Bio-Path Holdings Inc

    • Table Company Profile and Development Status of OncoGeneX Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of OncoGeneX Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of OncoGeneX Pharmaceuticals

    • Figure Revenue and Market Share Analysis of OncoGeneX Pharmaceuticals

    • Table Product and Service Introduction of OncoGeneX Pharmaceuticals

    • Table Company Profile and Development Status of GlaxoSmithKline Plc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline Plc

    • Figure Sales and Growth Rate Analysis of GlaxoSmithKline Plc

    • Figure Revenue and Market Share Analysis of GlaxoSmithKline Plc

    • Table Product and Service Introduction of GlaxoSmithKline Plc

    • Table Company Profile and Development Status of Mirna Therapeutics Inc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Mirna Therapeutics Inc

    • Figure Sales and Growth Rate Analysis of Mirna Therapeutics Inc

    • Figure Revenue and Market Share Analysis of Mirna Therapeutics Inc

    • Table Product and Service Introduction of Mirna Therapeutics Inc

    • Table Company Profile and Development Status of Ionis Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ionis Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Ionis Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Ionis Pharmaceuticals

    • Table Product and Service Introduction of Ionis Pharmaceuticals

    • Table Company Profile and Development Status of Olix Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Olix Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Olix Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Olix Pharmaceuticals

    • Table Product and Service Introduction of Olix Pharmaceuticals

    • Table Company Profile and Development Status of Rexahn Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Rexahn Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Rexahn Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Rexahn Pharmaceuticals

    • Table Product and Service Introduction of Rexahn Pharmaceuticals

    • Table Company Profile and Development Status of Acuitas Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Acuitas Therapeutics

    • Figure Sales and Growth Rate Analysis of Acuitas Therapeutics

    • Figure Revenue and Market Share Analysis of Acuitas Therapeutics

    • Table Product and Service Introduction of Acuitas Therapeutics

    • Table Company Profile and Development Status of Silence Therapeutics Plc

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Silence Therapeutics Plc

    • Figure Sales and Growth Rate Analysis of Silence Therapeutics Plc

    • Figure Revenue and Market Share Analysis of Silence Therapeutics Plc

    • Table Product and Service Introduction of Silence Therapeutics Plc

    • Table Company Profile and Development Status of miRagen Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of miRagen Therapeutics

    • Figure Sales and Growth Rate Analysis of miRagen Therapeutics

    • Figure Revenue and Market Share Analysis of miRagen Therapeutics

    • Table Product and Service Introduction of miRagen Therapeutics

    • Table Company Profile and Development Status of Benitec Biopharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Benitec Biopharma

    • Figure Sales and Growth Rate Analysis of Benitec Biopharma

    • Figure Revenue and Market Share Analysis of Benitec Biopharma

    • Table Product and Service Introduction of Benitec Biopharma

    • Table Company Profile and Development Status of Gene Signal

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Gene Signal

    • Figure Sales and Growth Rate Analysis of Gene Signal

    • Figure Revenue and Market Share Analysis of Gene Signal

    • Table Product and Service Introduction of Gene Signal

    • Table Company Profile and Development Status of Alnylam Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Alnylam Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Alnylam Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Alnylam Pharmaceuticals

    • Table Product and Service Introduction of Alnylam Pharmaceuticals

    • Table Company Profile and Development Status of Quark Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Quark Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Quark Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Quark Pharmaceuticals

    • Table Product and Service Introduction of Quark Pharmaceuticals

    • Table Company Profile and Development Status of Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)

    • Figure Sales and Growth Rate Analysis of Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)

    • Figure Revenue and Market Share Analysis of Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)

    • Table Product and Service Introduction of Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals)

    • Table Company Profile and Development Status of Sanofi-Genzyme

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi-Genzyme

    • Figure Sales and Growth Rate Analysis of Sanofi-Genzyme

    • Figure Revenue and Market Share Analysis of Sanofi-Genzyme

    • Table Product and Service Introduction of Sanofi-Genzyme

    • Table Company Profile and Development Status of Gradalis

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Gradalis

    • Figure Sales and Growth Rate Analysis of Gradalis

    • Figure Revenue and Market Share Analysis of Gradalis

    • Table Product and Service Introduction of Gradalis


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.